Epysqli Injection, Solution
NDC Package 51759-208-13
Package Information
Epysqli (eculizumab-aagh) injection is ePYSQLI is contraindicated for initiation in patients with unresolved serious Neisseria meningitidis infection [see Warnings and Precautions (5.1)]. This formulation utilizes a injection, solution delivery system. Marketed by Teva Pharmaceuticals Usa, Inc., this product is identified by NDC 51759-208 and is authorized under FDA application BLA761340.
Identification & Billing
- RxCUI: 2706338 - eculizumab-aagh 300 MG in 30 ML Injection
- RxCUI: 2706338 - 30 ML eculizumab-aagh 10 MG/ML Injection
- RxCUI: 2706338 - eculizumab-aagh 300 MG per 30 ML Injection
- RxCUI: 2706345 - Epysqli 300 MG in 30 ML Injection
- RxCUI: 2706345 - 30 ML eculizumab-aagh 10 MG/ML Injection [Epysqli]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 51759 - Teva Pharmaceuticals Usa, Inc.
- 51759-208 - Epysqli
- 51759-208-13 - 1 VIAL, SINGLE-DOSE in 1 CARTON / 30 mL in 1 VIAL, SINGLE-DOSE
- 51759-208 - Epysqli
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 51759-208-13 identifies a specific commercial package of 1 vial, single-dose in 1 carton / 30 ml in 1 vial, single-dose of Epysqli, a human prescription drug labeled by Teva Pharmaceuticals Usa, Inc.. This product is billed per "ML" milliliter and contains an estimated amount of 30 billable units per package. This injection, solution is formulated for intravenous use and contains eculizumab as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Teva Pharmaceuticals Usa, Inc. on April 07, 2025. The current certification is valid through December 31, 2027.
How is this Teva Pharmaceuticals Usa, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 51759020813. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 30 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.